Resolvins are potent analgesics for arthritic pain.

Journal Article (Journal Article)

Arthritis-associated inflammatory pain represents a serious medical problem worldwide. Current treatments for arthritic pain are not very effective and cause unwanted side effects. Resolvins, including the resolvin D and resolvin E series, are a family of novel endogenous lipid mediators derived from ω-3 polyunsaturated fatty acids and display potent anti-inflammatory and pro-resolution actions in animal models of inflammation. Emerging evidence also points to a potent anti-hyperalgesic role of resolvins in animal models of inflammatory pain. The study by Lima-Garcia et al. in this issue of the BJP demonstrated that systemic treatment with 17(R)-hydroxy-docosahexaenoic acid (17(R)HDoHE), the precursor of resolvin D series and its product, aspirin-triggered resolvin D1 (AT-RvD1), at very low doses (1 µg·kg(-1)), reduced inflammatory pain in an adjuvant-induced arthritis model. Particularly 17(R)HDoHE reduced joint stiffness but not paw and joint oedema. Given their potency and safety profile, resolvins may represent a new class of analgesics well suited to treating inflammatory pain associated with arthritis. LINKED ARTICLE This article is a commentary on Lima-Garcia et al., pp. 278-293 of this issue. To view this paper visit

Full Text

Duke Authors

Cited Authors

  • Xu, Z-Z; Ji, R-R

Published Date

  • September 2011

Published In

Volume / Issue

  • 164 / 2

Start / End Page

  • 274 - 277

PubMed ID

  • 21418190

Pubmed Central ID

  • PMC3174408

Electronic International Standard Serial Number (EISSN)

  • 1476-5381

Digital Object Identifier (DOI)

  • 10.1111/j.1476-5381.2011.01348.x


  • eng

Conference Location

  • England